Combination Trial Debate Energizes Keystone Symposium
Combination therapies may work where single drugs fall short, but testing them in AD may prove challenging.
6397 RESULTS
Sort By:
Combination therapies may work where single drugs fall short, but testing them in AD may prove challenging.
The 2014 Alzheimer’s Association report finds that women bear the brunt of AD, being more likely to develop the disease or care for someone with AD full time.
A Keystone symposium underscores the role of lysosomal dysfunction and vesicle trafficking in neurodegenerative disease.
Keystone symposium highlights new strategies in the quest to find the biomarkers of Parkinson’s disease.
Keystone presenters pulled out new tools to make connections between genetics and disease.
PINK1 mutations cripple mitochondrial energy production, raising new questions about Parkinson’s disease.
An antioxidant thought to boost mitochondrial function came up short in a large multicenter trial for PD treatment.
Astrocytes kindle neuronal hyperexcitability in mouse models of Huntington’s.
IMAGINE that: Amyloid deposition shrinks in both treatment and placebo groups, dealing a blow to the anti-aggregation drug PBT2.
When a calcium sensor disappears from dendritic spines, synapse loss soon follows in Alzheimer’s models, aging mice, and diseased human brains.
Hardening of the arteries correlated with greater amyloid deposition in a longitudinal study, strengthening ties between cardiovascular disease and Alzheimer’s.
The most detailed connectivity map for the mammalian brain to date will allow investigators to track neuronal networks at an unprecedented scale.
A new link between two proteins tied to Parkinson’s has implications for the disease and beyond.
As the adage goes, an ounce of prevention is worth a pound of cure. A new journal aims to find out if this is true for Alzheimer’s.
The April issue of Health Affairs is dedicated to Alzheimer’s. Authors gathered in Washington, D.C., to articulate how world policy could take shape.
No filters selected